Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | KEYNOTE-355: pembrolizumab in triple-negative breast cancer

Heather McArthur • 3 Jun 2020
ASCO 2020
Breast Cancer Antibodies Carboplatin Gemcitabine Nab-paclitaxel Paclitaxel Pembrolizumab
KEYNOTE-355

Heather McArthur, MD, MPH, of Cedars-Sinai Medical Center, Los Angeles, CA, outlines the findings from the KEYNOTE-355 trial (NCT02819518), a Phase III study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Heather McArthur

TROPION-Breast04: Dato-DXd and durvalumab in TNBC or HR-low/HER2- breast cancer
2:05
TROPION-Breast04: Dato-DXd and durvalumab in TNBC or HR-low/HER2- breast cancer
Heather McArthur • 13 Dec 2023
Management of ER+ breast cancer with checkpoint inhibitors
1:56
Management of ER+ breast cancer with checkpoint inhibitors
Heather McArthur • 13 Dec 2023
How can we best sequence ADCs in breast cancer?
1:37
How can we best sequence ADCs in breast cancer?
Heather McArthur • 13 Dec 2023
Managing ADC-related toxicity in breast cancer
1:51
Managing ADC-related toxicity in breast cancer
Heather McArthur • 13 Dec 2023

Related Videos

Omitting adjuvant radiotherapy in older patients with early-stage breast cancer
2:12
Omitting adjuvant radiotherapy in older patients with early-stage breast cancer
Lotte Bouwman • 24 Oct 2026
When can endocrine therapy be omitted in early breast cancer?
3:26
When can endocrine therapy be omitted in early breast cancer?
Lotte Bouwman • 24 Oct 2026
How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals